论文部分内容阅读
目的探讨TP方案和GP方案对晚期非小细胞肺癌(NSCLC)的临床疗效。方法 84例晚期NSCLC随机分为TP组和GP组,至少2个周期以上的化疗,比较两组方案的近期疗效、不良反应及KPS评分。结果 TP和GP两组近期疗效的有效率分别为40.0%和45.5%;两组不良反应主要表现为骨髓抑制和消化道反应,TP组脱发高于GP组;KPS评分改善率分别为27.5%和34.1%。结论 TP和GP方案对晚期NSCLC均有较好的临床疗效,化疗不良反应均可耐受,均可作为晚期NSCLC的一线治疗方案。
Objective To investigate the clinical efficacy of TP regimen and GP regimen in patients with advanced non-small cell lung cancer (NSCLC). Methods Eighty-four patients with advanced NSCLC were randomly divided into two groups: TP group and GP group. At least two cycles of chemotherapy were performed. The short-term efficacy, adverse reactions and KPS scores were compared between the two groups. Results The effective rates of the two groups were 40.0% and 45.5%, respectively. Adverse reactions of the two groups were mainly myelosuppression and digestive tract reaction. The rate of alopecia in TP group was higher than that in GP group. The improvement rate of KPS was 27.5% and 34.1%. Conclusion Both TP and GP regimens have good clinical efficacy in advanced NSCLC. Adverse reactions to chemotherapy can be tolerated, and both can be used as first-line treatment for advanced NSCLC.